Contrary to our results, research in lung cancer adenocarcinoma has demonstrated that PPP1R17 can be used as biomarkers as it was specifically detected in stage III, which can help us detect cancer stage in tumor progression through cleft junction incompatibility, Wnt signaling, and GPCR signaling pathways54. Here, PPP1R17 is linked to cancer.